A Toxicologist's Viewpoint On Developing Oncology Drug Products

Source: Thermo Fisher Scientific

With oncology growth rates on the rise, pharma companies are pressured to develop and manufacture life-saving therapies with speed and agility. Cancer growth rates are driven by environmental factors, lifestyle choices, and an aging population. Approximately 42% of the oncology market pipeline is attributed to oral solid doses.* Since oncology drugs are commonly categorized as highly potent, they require various handling and safety strategies.

In this webinar, toxicologist Joe Galati discusses:

  • Criteria for evaluating highly potent small molecules
  • Toxicity banding systems
  • Downgrading a molecule from high potent to low potent:
  • Safety and handling strategies

*Source: IQVIA- Global MIDAS Edition Includes antineoplastic agents (L01) and endocrine therapy (L02)- 248 molecules, OSD includes: tablets, ODT, capsules

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online